TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome
Brief Summary: The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary syndrome compared with placebo.


Options:
A: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Drug: Matching placebo for Rivaroxaban arm (Warfarin placebo) | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin, Drug: Matching placebo for Warfarin arm (Rivaroxaban placebo) | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Matching placebo for Rivaroxaban arm (Warfarin placebo); Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Matching placebo for Warfarin arm (Rivaroxaban placebo); Assigned to Arm(s): Warfarin
B: Arm Label: Rivaroxaban 2.5 mg bid; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban 2.5 mg, Drug: Standard of care | Arm Label: Rivaroxaban 5 mg bid; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban 5 mg, Drug: Standard of care | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Standard of care | Intervention Type: DRUG; Name: Rivaroxaban 2.5 mg; Assigned to Arm(s): Rivaroxaban 2.5 mg bid | Intervention Type: DRUG; Name: Rivaroxaban 5 mg; Assigned to Arm(s): Rivaroxaban 5 mg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Standard of care; Assigned to Arm(s): Placebo, Rivaroxaban 2.5 mg bid, Rivaroxaban 5 mg bid
C: Arm Label: Acute Coronary Syndrome; Type: N/A; Interventions: Other: Thrombin generation assays, TEG and GTT | Intervention Type: OTHER; Name: Thrombin generation assays, TEG and GTT; Assigned to Arm(s): Acute Coronary Syndrome
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor 90 mg | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor 60 mg | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ticagrelor Placebo | Intervention Type: DRUG; Name: Ticagrelor 90 mg; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ticagrelor 60 mg; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ticagrelor Placebo; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome
Brief Summary: The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary syndrome compared with placebo.


Options:
A: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Rivaroxaban 2.5 mg bid; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban 2.5 mg, Drug: Standard of care | Arm Label: Rivaroxaban 5 mg bid; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban 5 mg, Drug: Standard of care | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Standard of care | Intervention Type: DRUG; Name: Rivaroxaban 2.5 mg; Assigned to Arm(s): Rivaroxaban 2.5 mg bid | Intervention Type: DRUG; Name: Rivaroxaban 5 mg; Assigned to Arm(s): Rivaroxaban 5 mg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Standard of care; Assigned to Arm(s): Placebo, Rivaroxaban 2.5 mg bid, Rivaroxaban 5 mg bid
C: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Drug: Matching placebo for Rivaroxaban arm (Warfarin placebo) | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin, Drug: Matching placebo for Warfarin arm (Rivaroxaban placebo) | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Matching placebo for Rivaroxaban arm (Warfarin placebo); Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Matching placebo for Warfarin arm (Rivaroxaban placebo); Assigned to Arm(s): Warfarin
D: Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Ticagrelor | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centre, Randomised, Prospective, Single-blinded, Controlled Study to Investigate the Efficacy and Safety of a Standardised Maintenance Dosage Regimen of Intravenous Ferric Carboxymaltose (FERINJECT®) Versus Placebo in Patients With Iron Deficiency Caused by Inflammatory Bowel Disease
Brief Summary: The aim of this study is to evaluate the treatment of iron deficiency in IBD patients.


Options:
A: Intervention Type: DRUG; Name: Iron Sucrose IV 200mg, once a week, for 5 weeks; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ferrous sulfate 200mg PO TID, for 8 weeks; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FE; Type: EXPERIMENTAL; Interventions: Drug: Ferric carboxymaltose | Arm Label: EPOFE; Type: EXPERIMENTAL; Interventions: Drug: Ferric carboxymaltose, Drug: Erythropoietin | Intervention Type: DRUG; Name: Ferric carboxymaltose; Assigned to Arm(s): EPOFE, FE | Intervention Type: DRUG; Name: Erythropoietin; Assigned to Arm(s): EPOFE | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Ferumoxytol; Type: EXPERIMENTAL; Interventions: Drug: Ferumoxytol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Ferumoxytol; Assigned to Arm(s): Ferumoxytol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Ferinject; Type: EXPERIMENTAL; Interventions: Drug: Ferinject | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ferinject | Intervention Type: DRUG; Name: Ferinject; Assigned to Arm(s): Ferinject, Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Two Different Treatment Strategies in Patients With Major Depressive Disorder Not Exhibiting Improvement on Escitalopram Treatment: Early vs. Delayed Intervention Strategy
Brief Summary: This study investigates two different approaches to the change in antidepressant treatment when an initial treatment is not effective: early intervention or delayed intervention.

Two hypothesis will be tested:

1. that time to confirmed response is shorter in the early intervention strategy vs. delayed intervention strategy
2. that the time to confirmed remission is shorter in the early intervention strategy compared to delayed intervention strategy.


Options:
A: Arm Label: Early Intervention; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine Hydrochloride, Drug: Escitalopram | Arm Label: Delayed Intervention; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine Hydrochloride, Drug: Escitalopram | Intervention Type: DRUG; Name: Duloxetine Hydrochloride; Assigned to Arm(s): Delayed Intervention, Early Intervention | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Delayed Intervention, Early Intervention
B: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A
C: Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Paroxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Quetiapine fumarate; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Placebo-controlled Study of Two Treatment Strategies Based on Tocilizumab (TCZ) With or Without Methotrexate (MTX) and Possible Addition of Other Disease-modifying Anti-rheumatic Drugs (DMARDs) in Patients...
Brief Summary: This 2 arm study will compare 2 treatment strategies based on tocilizumab in combination with methotrexate or placebo in patients with moderate to severe rheumatoid arthritis. Patients receiving methotrexate treatment will be randomized to receive either a) tocilizumab 8 mg intravenous (iv) every 4 weeks + methotrexate orally (po) weekly or b) tocilizumab 8 mg iv every 4 weeks + placebo po weekly. After the first 24 weeks of blinded treatment, treatment adjustments (increase or decrease of treatment intensity) may be introduced at intervals, based on response. The anticipated time on study treatment is up to 3 years, and the target sample size is approximately 470 patients.


Options:
A: Arm Label: Tocilizumab + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: methotrexate | Arm Label: Tocilizumab + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: placebo | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): Tocilizumab + Methotrexate, Tocilizumab + Placebo | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Tocilizumab + Methotrexate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Tocilizumab + Placebo
B: Arm Label: Tocilizumab 162 mg sc; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab 162 mg | Arm Label: Placebo sc; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tocilizumab 162 mg; Assigned to Arm(s): Tocilizumab 162 mg sc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo sc
C: Arm Label: Abatacept + Methotrexate (Double-blind period); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Placebo + Methotrexate (Double-blind period); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate (Double-blind period) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate (Double-blind period)
D: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: C-Cure - Safety, Feasibility and Efficacy of Guided Bone Marrow-derived Mesenchymal Cardiopoietic Cells for the Treatment of Heart Failure Secondary to Ischemic Cardiomyopathy
Brief Summary: The purpose of this clinical trial is to evaluate the feasibility, safety and efficacy of left ventricular endocardial injection of guided bone marrow-derived cardiopoietic cells (C-Cure) in the setting of chronic heart failure secondary to ischemic cardiomyopathy.


Options:
A: Arm Label: Optimal Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: optimal therapy for cardiaca failure | Arm Label: cell therapy; Type: EXPERIMENTAL; Interventions: Procedure: cell | Intervention Type: DRUG; Name: optimal therapy for cardiaca failure; Assigned to Arm(s): Optimal Therapy | Intervention Type: PROCEDURE; Name: cell; Assigned to Arm(s): cell therapy
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: C-Cure | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: C-Cure; Assigned to Arm(s): 1
C: Arm Label: Ixmyelocel-T; Type: EXPERIMENTAL; Interventions: Biological: Ixmyelocel-T | Arm Label: Standard of Care; Type: OTHER; Interventions: Other: Standard of Care | Intervention Type: BIOLOGICAL; Name: Ixmyelocel-T; Assigned to Arm(s): Ixmyelocel-T | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Standard of Care
D: Arm Label: Ixmyelocel-T; Type: EXPERIMENTAL; Interventions: Biological: Ixmyelocel-T | Arm Label: Vehicle Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Vehicle Control | Intervention Type: BIOLOGICAL; Name: Ixmyelocel-T; Assigned to Arm(s): Ixmyelocel-T | Intervention Type: OTHER; Name: Vehicle Control; Assigned to Arm(s): Vehicle Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: C-Cure - Safety, Feasibility and Efficacy of Guided Bone Marrow-derived Mesenchymal Cardiopoietic Cells for the Treatment of Heart Failure Secondary to Ischemic Cardiomyopathy
Brief Summary: The purpose of this clinical trial is to evaluate the feasibility, safety and efficacy of left ventricular endocardial injection of guided bone marrow-derived cardiopoietic cells (C-Cure) in the setting of chronic heart failure secondary to ischemic cardiomyopathy.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: C-Cure | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: C-Cure; Assigned to Arm(s): 1
B: Arm Label: Placebo Injections; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Active Stem Cell Injections; Type: EXPERIMENTAL; Interventions: Biological: Adult stem cells | Intervention Type: BIOLOGICAL; Name: Adult stem cells; Assigned to Arm(s): Active Stem Cell Injections | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Injections
C: Intervention Type: PROCEDURE; Name: Bone Marrow Stem Cell Therapy combined CABG; Assigned to Arm(s): N/A
D: Arm Label: Low-dose shock wave treatment & Placebo; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intracoronary stem cell therapy | Arm Label: low-dose shock-wave treatment & Cell therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intracoronary stem cell therapy | Arm Label: High-dose shock-wave treatment & Placebo; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intracoronary stem cell therapy | Arm Label: High-dose shock-wave treatment & cell therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intracoronary stem cell therapy | Arm Label: Placebo shock-wave treatment & cell therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intracoronary stem cell therapy | Intervention Type: PROCEDURE; Name: intracoronary stem cell therapy; Assigned to Arm(s): High-dose shock-wave treatment & Placebo, High-dose shock-wave treatment & cell therapy, Low-dose shock wave treatment & Placebo, Placebo shock-wave treatment & cell therapy, low-dose shock-wave treatment & Cell therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lawrence Latino Diabetes Prevention Project
Brief Summary: The Lawrence Latino Diabetes Prevention Project (LLDPP) is a community-based translational research study which aims to reduce the risk of diabetes among Latinos who have a \>30% probability of developing diabetes in the next 7.5 years per a predictive equation. The project was conducted in Lawrence, Massachusetts; a predominantly Caribbean-origin urban Latino community. Individuals were identified primarily from a community health center's patient panel, screened for study eligibility, randomized to either a usual care or a lifestyle intervention condition, and followed for one year.


Options:
A: Intervention Type: BEHAVIORAL; Name: lifestyle intervention; Assigned to Arm(s): N/A
B: Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Communities That Care Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Communities That Care | Intervention Type: BEHAVIORAL; Name: Communities That Care; Assigned to Arm(s): Communities That Care Intervention
C: Arm Label: Peer-Led Stroke Recurrence Prevention Education; Type: EXPERIMENTAL; Interventions: Behavioral: Prevent Return of Stroke | Arm Label: Usual Care (Delayed Intervention); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Prevent Return of Stroke | Intervention Type: BEHAVIORAL; Name: Prevent Return of Stroke; Assigned to Arm(s): Peer-Led Stroke Recurrence Prevention Education | Intervention Type: BEHAVIORAL; Name: Prevent Return of Stroke; Assigned to Arm(s): Usual Care (Delayed Intervention)
D: Arm Label: Passive Arm #1; Type: EXPERIMENTAL; Interventions: Behavioral: Active Arm #1, #2, Passive Arm #1, #2 | Arm Label: Passive Arm #2; Type: EXPERIMENTAL; Interventions: Behavioral: Active Arm #1, #2, Passive Arm #1, #2 | Arm Label: Active Arm #1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Arm #1, #2, Passive Arm #1, #2 | Arm Label: Active Arm #2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Arm #1, #2, Passive Arm #1, #2 | Intervention Type: BEHAVIORAL; Name: Active Arm #1, #2, Passive Arm #1, #2; Assigned to Arm(s): Active Arm #1, Active Arm #2, Passive Arm #1, Passive Arm #2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Activity in Women With Infants
Brief Summary: This is a study testing ways to motivate new mothers to become more physically active over a one year period.


Options:
A: Arm Label: 1- physical activity tailored; Type: EXPERIMENTAL; Interventions: Behavioral: physical activity tailored | Arm Label: 2 - physical activity standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: physical activity standard | Intervention Type: BEHAVIORAL; Name: physical activity tailored; Assigned to Arm(s): 1- physical activity tailored | Intervention Type: BEHAVIORAL; Name: physical activity standard; Assigned to Arm(s): 2 - physical activity standard
B: Arm Label: COHS administered fluoride varnish and oral health education; Type: EXPERIMENTAL; Interventions: Device: Fluoride varnish, Behavioral: Oral health education | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Dental services delivered by the Indian Health Service. | Intervention Type: DEVICE; Name: Fluoride varnish; Assigned to Arm(s): COHS administered fluoride varnish and oral health education | Intervention Type: BEHAVIORAL; Name: Oral health education; Assigned to Arm(s): COHS administered fluoride varnish and oral health education | Intervention Type: OTHER; Name: Dental services delivered by the Indian Health Service.; Assigned to Arm(s): Usual care
C: Intervention Type: DRUG; Name: Fluoride varnish; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Home Visiting; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Activity in Women With Infants
Brief Summary: This is a study testing ways to motivate new mothers to become more physically active over a one year period.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Exercise, and Breastfeeding Intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diet, Exercise, and Breastfeeding Intervention; Assigned to Arm(s): Intervention
B: Arm Label: 1- physical activity tailored; Type: EXPERIMENTAL; Interventions: Behavioral: physical activity tailored | Arm Label: 2 - physical activity standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: physical activity standard | Intervention Type: BEHAVIORAL; Name: physical activity tailored; Assigned to Arm(s): 1- physical activity tailored | Intervention Type: BEHAVIORAL; Name: physical activity standard; Assigned to Arm(s): 2 - physical activity standard
C: Arm Label: Lifestyle, follow-up, early care, standard care high/low risk; Type: OTHER; Interventions: Behavioral: Lifestyle: diet and exercise | Arm Label: Close follow-up; Type: OTHER; Interventions: Behavioral: Close follow-up: reporting diaries of food and exercise | Intervention Type: BEHAVIORAL; Name: Lifestyle: diet and exercise; Assigned to Arm(s): Lifestyle, follow-up, early care, standard care high/low risk | Intervention Type: BEHAVIORAL; Name: Close follow-up: reporting diaries of food and exercise; Assigned to Arm(s): Close follow-up
D: Arm Label: energy-restricted, CHO-restricted diet; Type: EXPERIMENTAL; Interventions: Other: energy-restricted, CHO-restricted diet | Arm Label: energy-restricted, CHO-rich diet; Type: ACTIVE_COMPARATOR; Interventions: Other: energy-restricted, CHO-rich diet | Intervention Type: OTHER; Name: energy-restricted, CHO-restricted diet; Assigned to Arm(s): energy-restricted, CHO-restricted diet | Intervention Type: OTHER; Name: energy-restricted, CHO-rich diet; Assigned to Arm(s): energy-restricted, CHO-rich diet

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Activity in Women With Infants
Brief Summary: This is a study testing ways to motivate new mothers to become more physically active over a one year period.


Options:
A: Arm Label: PEPAF; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental Programme for Physical Activity Promotion | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Experimental Programme for Physical Activity Promotion; Assigned to Arm(s): PEPAF | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Mini Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Mini Booster | Arm Label: Full Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Full Booster | Intervention Type: BEHAVIORAL; Name: Mini Booster; Assigned to Arm(s): Mini Booster | Intervention Type: BEHAVIORAL; Name: Full Booster; Assigned to Arm(s): Full Booster
C: Arm Label: 1- physical activity tailored; Type: EXPERIMENTAL; Interventions: Behavioral: physical activity tailored | Arm Label: 2 - physical activity standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: physical activity standard | Intervention Type: BEHAVIORAL; Name: physical activity tailored; Assigned to Arm(s): 1- physical activity tailored | Intervention Type: BEHAVIORAL; Name: physical activity standard; Assigned to Arm(s): 2 - physical activity standard
D: Arm Label: Tailored Physical Activity Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Physical Activity Intervention | Arm Label: No Tailored Physical Activity Intervention Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tailored Physical Activity Intervention; Assigned to Arm(s): Tailored Physical Activity Intervention Group

Answer: C